|Articles|May 29, 2018

Study on Infection Prevention Programs Find Urgent Need for Increased Staffing

A new study finds that most infection prevention and control programs require more staff and existing models are woefully inadequate.

How many infection preventionists should hospitals employ? Hospitals spend a lot of time looking at nursing ratios for patients and ensuring enough staff are on the units, but what about the infection prevention program? There have been only a handful of studies to truly address the staffing of infection prevention and control programs (IPC) within health care facilities and as the duties become more diverse, such analyses are critical to reinforcing support.

The 2014 Ebola cluster in Dallas, Texas, underscored the importance of infection prevention practices and preparedness in health care, which adds another layer of complexities to health care programs. Infection preventionists (IPs) who make up the back-bone of these teams are responsible for a range of duties that include surveillance and investigation of health care-associated infections, environment of care rounding, national reporting for quality metrics, isolation rounding, communicable disease reporting, and more. As the threat of emerging infectious diseases and hospital preparedness has become a hot topic, this has also been added to the list of IP duties.

A previous study from 2002, found that infection control staffing was recommended as 1 full-time employee (FTE) IP for every 250 acute care beds; however, the authors recommended that should be changed to 0.8 to 1.0 IP for every 100 occupied acute care beds. Although this was a welcome update, it has become increasingly obvious to infection control program staff and their IPs, that the scope of practice is expanding.

Now, a new study sought to address this through a comprehensive quantitative needs assessment regarding the number of IPs needed to build an effective infection prevention program.

For the study, the research team evaluated a large, nonprofilt health care system that included 34 hospitals, and nearly 600 physician clinic and other outpatient services, which is divided across 9 regions. To truly understand the needs of each hospital, the investigators spent an entire day, on-site in each region to meet with key stakeholders (including those outside the infection prevention team, such as the chief nursing officer and chief medical officer), among other actions. They then compiled all data collected via survey and addressed the IPC duties at the locations that required an IP to be physically present (ie, performing isolation rounding, environment of care rounding, etc.) and its frequency.

The investigators then worked to develop a staffing model by looking at, “the total IPC FTE needs identified during the quantitative assessment [and comparing it] with the current IPC FTE status within the region. Gaps were highlighted based on care setting, and each regional team determined where and how the needed IPC resources should be applied. A model of an ideal program was created for each region based on the discussion and gaps identified.”

Following this analysis, the investigators established high and low benchmarks for IPC FTE needs based off the literature review (number of FTEs calculated using literature review of 0.5 FTE per 100 beds versus 1.0 FTE per 100 beds), and also the calculated actual FTE need using the quantitative assessment method.

For those of us in the infection prevention industry, the results weren’t surprising. The calculated FTE needs based on the quantitative assessment was seriously higher. If one considers that surveillance alone accounts for over 50% of the IP’s daily time, it’s not surprising that the needs aren’t being met. The researchers found that when aggregated across the system, a new benchmark was established: 1.0 FTE IP per 69 beds for true infection prevention oversight.

Although there is a desperate need for more research to establish adequate IP staffing in infection prevention programs, this study represents an updated model and benchmark for programs to utilize. At its core, investing in infection prevention is investing in patient and health care worker safety, something we are all striving to improve.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.